| Assessment Status | Rapid Review complete |
| HTA ID | 22037 |
| Drug | Buprenorphine/Naloxone |
| Brand | Zubsolv® |
| Indication | As substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who agreed to be treated for addiction. |
| Assessment Process | |
| Rapid review commissioned | 26/05/2022 |
| Rapid review completed | 21/06/2022 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that Zubsolv® be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
